3
agents. Among the synthesized compounds, compound 7a, 9b
and 9d showed excellent antimicrobial and antidiabetic activity
in comparison with standard drugs in in vitro studies. The SAR
study of the title compounds inferred that, the bio-activity of
these compounds are strongly dependent on the nature of the
substituents at the ether linked aryl ring attached to the pyrazole
unit, along with the substituent linked to the benzimidazole unit.
In vivo and cytotoxicity investigations of the best active
compounds 7a, 9b and 9d are necessary to fully appraise the
potential of these compounds.
Acknowledgments
One of the authors (D.S.D) is grateful to Rajiv Gandhi
National Fellowship (DV5/130(6)/RGNF/2011-2012 dated 08-
08-2011) UGC, New Delhi, for providing the necessary fund to
carry out the research at University of Mysore.
Supplementary Material
Supplementary data (Experimental details, NMR, MS and
elementary analysis) associated with this article can be found, in
the online version, at
Figure 1 Docking of (A) 7a, (B) 9b, (C) 9d against α-amylase and (D) 9b
showing hydrogen bond.
References and notes
Rational drug design helps to expedite the drug designing
process, which involves variety of methods to identify novel
compounds. One such method is the docking of the drug
molecule with the receptor. In order to gain more insight into the
1
2
.
.
Peara, S.; Patterson, T. F. Clin. Infect. Dis. 2002, 35, 1073.
Giulia, M.; Luisa, M.; Paola, F.; Silvia, S.; Angelo, R.; Luisa, M.;
Francesco, B.; Roberta, L.; Chiara, M.; Valeria, M.; Paolo, L. C.;
Elena, T. Bioorg. Med. Chem. 2004, 12, 5465.
interaction between these new series of compounds 7(a
(a f) with α-amylase and α-glucosidase molecular docking
studies were performed. As in vitro study of compounds 7(a f)
and 9(a f) showed high inhibition activity against α-amylase
−
f) and
9
−
3. Vincent, T. A.; J. Antimicrob. Chemother. 1999, 44, 151.
World Health Organization Consultation: Definition, diagnosis
and classification of diabetes mellitus and its complications. Part
4
.
−
−
1
: diagnosis and classification of diabetes mellitus. Report of a
WHO Consultation Geneva; 1999.
5. Mc Cune, L. M.; Johns, T. J Ethnopharmacol. 2002, 82, 197.
when compared to α-glucosidase, α-amylase was selected for
molecular docking study.
6
.
Rhabasa L. R.; Chiasson, J. L. α-glucosidase inhibitors; In
Defronzo, R. A.; Ferrannini, E.; Keen, H.; Zimmet, P. (Eds.).
International textbook of diabetes mellitus, 3rd ed.; John Wiley:
UK, Vol. 1, 2004.
Wustrow, D. J.; Capiris, T.; Rubin, R.; Knobelsdorf, J. A.;
Akunne, H.; Davis, M. D.; MacKenzie, R.; Pugsley, T. A.; Zoski,
K. T.; Heffner, T. G.; Wise, L. D. Bioorg. Med. Chem. Lett. 1998,
Automated docking was used to assess the binding modes and
conformation of the ligand molecules. Molecular docking study
is a well-established technique to determine the interaction of
two molecules and find the best orientation of ligand would form
a complex with overall minimum energy. All the compounds
7
.
7
(a
ranging from -6.32 to -8.68 kJ/mol with α-amylase (PDB Code:
PPI) (Table 4). Among the molecules tested for docking study,
−
f) and 9(a f) were found to have minimum binding energy
−
8
, 2067.
8. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.;
Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J.
W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.;
Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.;
Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.;
Zhang, Y. Y.; Isakson, P. C. J. Med. Chem. 1997, 40, 1347.
9. Terrett, N. K.; Bell, A. S.; Brown, D.; Ellis, P. Bioorg. Med.
Chem. Lett. 1996, 6, 1819.
1
1
1
1
1
the compound ethyl 5-((6-(difluoromethoxy)-2-mercapto-1H-
benzo[d]imidazol-1-yl)methyl)-1,3-diphenyl-1H-pyrazole-4-
carboxylate 9b showed minimum binding energy -8.60 kJ/mol
with ligand efficiency of -0.23 which is due to dipole-dipole and
hydrogen bond interaction with the targeted protein. The 1PPI
comprises of twenty one active site residues, which are
promiscuous to the ligands. Out of which GLN 63, HIS 305, LYS
0. Gang, S.; Pengfei, L.; and Yu Rao. Org. Lett. 2011, 13, 1746.
1. Strecker, A.; Justus Liebigs Ann. Chem. 1850, 75, 27.
2. Domling, A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 39, 3168.
3. Kappe, C. O. Acc. Chem. Res. 2000, 33, 879.
200, GLY 306 and ASP 300 residues are directly interacting with
the ligands (7b, 7c, 7d, 7e, 7f, 9b and 9f), where as the ligands
14. Ningaiah, S.; Bhadraiah, U. K.; D. Shridevi Doddaramappa
Keshavamurthy, S.; Javarasetty, C. Bioorg. Med. Chem. Lett.
7a, 9a, 9c, 9d and 9e has no hydrogen bond interaction with the
2
014, 24, 245.
5. Zhou, C. H.; Wang, Y.; Current Medicinal Chemistry. 2012, 19,
39.
6. Wang, Y.; Zhou, C. H.; Science Sinica Chimica. 2011, 41 1429.
1
PPI. Most of the residues that are in close proximity to the
1
1
inhibitor are hydrophobic in nature. The docking study results
showed that the compounds 7(a f) and 9(a f) have good
2
−
−
inhibition constants. The details of docked score results of the
compounds with α-amylase are given in the Table 4 (see
supplementary material).
17. Srikantamurthy, N.; Shridevi Doddaramappa, D.; Chandra,
Mahendra, M.; Shubakara, K.; Umesha, K. B. Synthetic Commun,
2
014, 44, 2222.
1
8. Almansa, C.; Gomez, L. A.; Cavalcanti, F. L.; Arriba, A. F.;
Rafanell, J. D.; Form, J. G. J. Med. Chem. 1997, 40, 547.
9. Van Allan, Deacon, Org.Syn coll.vol.IV, 1963, 569.
In conclusion, we have synthesized a new series of “5-(O/N-
substituted)methylpyrazoles 7(a−f) and 9(a−f) and these
compounds were investigated for their in vitro antimicrobial and
antidiabetic activity. Subsequently, these novel classes of
compounds have emerged as potent antibacterial and antifungal
1
2
0. Sharada, L. N.; Satyanarayanareddy, G.S.; Sammaiah, B.;
Sumalatha, D. Asian Journal of Chemistry, 2013, 25 (14), 7959.
1. The optimized reaction condition of PTC-alkylation: ethyl 5-
2
(bromomethyl)-1,3-diphenyl-1H-pyrazole-4-carboxylate
5 were